



For immediate release: 21 April 2015

HVIVO PLC
("hVIVO" or the "Company")

Award of Share Options

hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, announces that on 21 April 2015 it awarded the following options over ordinary shares of 5.0p each in the Company to certain Directors:

| Name | Position | Number of Share Options Awarded | Exercise price per Share | Date of Vesting | Percentage of issued ordinary share capital |
|----------------|------------------------------------|---------------------------------|--------------------------|-----------------|---|
| Kym Denny | Chief Executive Officer | 111,193 | 337.25p | 21 April 2018 | 0.16% |
| Graham Yeatman | Chief Financial & Business Officer | 88,955 | 337.25p | 21 April 2018 | 0.13% |

For further information please contact:

hVIVO plc

+44 207 756 1300

Kym Denny (CEO)
Graham Yeatman (FD)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.